<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988620</url>
  </required_header>
  <id_info>
    <org_study_id>2019/01294</org_study_id>
    <nct_id>NCT04988620</nct_id>
  </id_info>
  <brief_title>Cold Stored Whole Blood in Cardiothoracic Surgery</brief_title>
  <official_title>Cold Stored Whole Blood in Treatment of Bleeding in Patients Undergoing Cardiothoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro platelet function and post-transfusion platelet recovery of platelets stored in&#xD;
      whole blood decline during storage. In this pilot randomized clinical trial we aim to&#xD;
      investigate the impact of storage time of whole blood on the effect and safety in treatment&#xD;
      of immediate blood loss in patients undergoing complex cardiothoracic surgery. The study is&#xD;
      designed as an exploratory superiority study to support feasibility and provide critical&#xD;
      guidance for future, more definitive randomized trials. In the study the test group will&#xD;
      receive CPD whole blood leukocyte-depleted with a platelet-sparing filter and stored for&#xD;
      15-21 days whereas the control group patients will receive leukocyte-depleted CPD whole blood&#xD;
      stored for less than 7 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A challenge for implementation of Whole Blood programs in civilian health services has been&#xD;
      an uncertainty regarding the impact of storage on the clinical effect of the whole blood&#xD;
      transfusion, especially when it comes to platelet function which is essential to hemostasis.&#xD;
      In vitro platelet function and post-transfusion platelet recovery decline with increasing&#xD;
      storage time of the whole blood.&#xD;
&#xD;
      In this pilot randomized clinical trial we aim to investigate the impact of storage time of&#xD;
      whole blood on the effect and safety in treatment of immediate blood loss in patients&#xD;
      undergoing complex cardiothoracic surgery. The study is designed as an exploratory&#xD;
      superiority study to support feasibility and provide critical guidance for future, more&#xD;
      definitive randomized trials. In the study the test group will receive CPD whole blood&#xD;
      leukocyte-depleted with a platelet-sparing filter and stored for 15-21 days whereas the&#xD;
      control group patients will receive leukocyte-depleted CPD whole blood stored for less than 7&#xD;
      days. A control group receiving standard care (blood component-based transfusion) may be&#xD;
      included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">June 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Test group ( Whole Blood stored for 15-21 days) versus Control group(s) (Whole Blood stored for less than 7 days, Whole Blood stored for 8-14 days and/or Standard Blood Component treatment)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The participant and clinical personell ordering and evalutaing the effect of transfusion will be blinded, so will also the investigators performing the statistical evaluation of the results. The project co-workers preparing the whole blood units and perforing laboratory analysis will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Comparison of postoperative immediate blood loss (measured by chest drain output and/or bleeding score) in patients receiving fresher or older cold stored whole blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood usage</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Comparison of amount of whole blood and blood components given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Coagulation measured as INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APTT</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Coagulation measured as APTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastography</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Thromboelastography (TEG6s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregometry</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Platelet aggregation measured by Multiplate impedance aggregometry (Mulitplate analyzer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte count</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Erythrocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Hematocrit or erytrocyte volume fraction, i.e.the volume percentage (vol%) of red blood cells (RBC) in blood,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen concentration</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Fibrinogen concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic profile</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Investigation of blood cell metabolism and metabolic profile by use of high resolution mass spectometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>White blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Hemolysis measured as Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haptoglobin</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Hemolysis measured as Haptoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Lactate dehydrogenase (LD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct antiglobin test</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Direct antiglobin test (DAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-A antibodies</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Anti-A antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-B antibodies</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Anti-B antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic agents</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Use of hemostatic agents (coagulation factor concentrates, fibriongen concentrate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medications</measure>
    <time_frame>24 hours (8:00 am morning after surgery)</time_frame>
    <description>Use of other medications potentially affecting bleeding (including tranexamacid, calcium etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Whole Blood stored for 15-21 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 15-21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole Blood stored for less than 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for less than 7 days. We aim at using as fresh as possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole Blood stored for 8-14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 8-14 days. This group may be added if deemed of interest after interim analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Blood Component</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group may be added for comparison if deemed of interest after interim analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole Blood transfusion</intervention_name>
    <description>In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.</description>
    <arm_group_label>Standard Blood Component</arm_group_label>
    <arm_group_label>Whole Blood stored for 15-21 days</arm_group_label>
    <arm_group_label>Whole Blood stored for 8-14 days</arm_group_label>
    <arm_group_label>Whole Blood stored for less than 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing cardiothoracic, cardiac, or aortic surgery&#xD;
&#xD;
          2. Patients with complex surgical procedures and expected cardiopulmonary bypass (CPB)&#xD;
             time over 120 minutes&#xD;
&#xD;
          3. Patients capable of providing informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not capable of providing informed consent to participate or who will not&#xD;
             provide informed consent&#xD;
&#xD;
          2. Patients with known congenital coagulopathies or hemostatic disorders (von Willebrands&#xD;
             Disease, hemophilia etc)&#xD;
&#xD;
          3. Patients with known erythrocyte- or platelet/HLA antibodies&#xD;
&#xD;
          4. Patients with a particular increased surgical risk with expected need of ECMO&#xD;
&#xD;
          5. Patients with preoperative EuroScore II â‰¥ 30&#xD;
&#xD;
        5. RhD negative patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einar K Kristoffersen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helse Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torunn O Apelseth, PhD</last_name>
    <phone>+4755972470</phone>
    <email>torunn.oveland.apelseth@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin G Hagen, MD</last_name>
    <phone>+4755972470</phone>
    <email>kristin.gjerde.hagen@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torunn O Apelseth, PhD</last_name>
      <phone>+4755972470</phone>
      <email>torunn.oveland.apelseth@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristin G Hagen, MD</last_name>
      <phone>+55972470</phone>
      <email>kristin.gjerde.hagen@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

